Intellia Therapeutics, Inc.

Healthcare

NASDAQ:NTLA · NASDAQ Global Market

Market Cap $1.71B Beta 1.81 P/E (TTM) -4.6

$15.67 +0.14%

+$0.02 today

52W Low $7.95High $28.25

Vol 7.50M · Avg 6.11M

EPS (TTM) -$3.33Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+69.77%

Period High

$27.98

Period Low

$8.04

Latest

$15.67

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Spyre Therapeutics, Inc.

NASDAQ:SYRE

$5.34B

Pharvaris N.V.

NASDAQ:PHVS

$2.29B

BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

$1.91B

Stoke Therapeutics, Inc.

NASDAQ:STOK

$1.87B

Immunome, Inc.

NASDAQ:IMNM

$1.73B

Zymeworks Inc.

NASDAQ:ZYME

$1.67B

Biohaven Ltd.

NYSE:BHVN

$1.42B

Wave Life Sciences Ltd.

NASDAQ:WVE

$1.16B

Zenas BioPharma, Inc.

NASDAQ:ZBIO

$860.25M

Upstream Bio, Inc.

NASDAQ:UPB

$339.31M

What is the latest NTLA filing?

The latest filing shown is 8-K dated Jun 15, 2026.

How many recent filings does NTLA have?

Intrinsic Alpha currently shows 20 recent filings for NTLA.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.